Rewatching the August Investor Update again regarding Paul's...

Rewatching the August Investor Update again regarding Paul's comments on the PLA code which was 4 weeks ago. He mentions that "just last week" which was 5 weeks ago now, that the panel recommended them to the final decisioning team which are due to meet within roughly the next week which will set the reimbursement rate for Febridx.

Are we expecting news within the next week of confirmation of this code?

25 Febridx partnerships so far and still engaging with major distributors and global partners.

I am thoroughly curious where people place revenue for a full quarter next quarter?

$700,000USD for the tail end of the season in December last year with a following $300,000USD - primarily Viradx.

Are we going to see $1M+USD in sales in the first quarter? Does this then intrigue the market to substantially rerate the share price? Or would we need to see multiples of this per quarter before a rerate occurs?

Or is CLIA waiver the only thing which is going to trigger an FDA approval like jump?